Chrysos (C79) H1 2025 earnings summary

Executive summary

• Revenue for 1H FY25 rose 54% year-on-year to $29.1 million, driven by global adoption of PhotonAssay technology, record sample volumes, and international expansion, especially in EMEA and the Americas.

• EBITDA increased 150% to $5.7 million, with margin expanding to 20% from 12% year-on-year, reflecting operational efficiencies and economies of scale.

• Six new lease agreements were signed, bringing total contracted units to 56 and deployed units to 34 as of period end.

• The company maintains a strong cash position of $26.9 million, supported by a $95 million debt facility, with an initial drawdown of $18 million post-period.

• Market penetration continues to grow, with PhotonAssay now used by seven of the world's 15 largest gold miners and three of the four largest laboratory companies.

Financial highlights

• Minimum Monthly Assay Payments (MMAP) accounted for 89% of revenue ($25.8 million), with Additional Assay Charges (AAC) at 11% ($3.3 million), both showing strong year-on-year growth.

• Gross profit margins for PhotonAssay units remain in the 70%-80% range.

• Operating cash flow increased significantly year-on-year, reaching $6.14 million, enabling reinvestment in growth.

• Net loss after tax narrowed to $2.6 million from $3.1 million year-on-year, reflecting higher depreciation and finance costs.

• Capital expenditure increased to $41.9 million, supporting global deployment.

Outlook and guidance

• Revenue is tracking toward the lower end of FY25 guidance ($60m–$70m), with EBITDA below the midpoint of the $9m–$19m range.

• Focus remains on accelerating deployment cadence, broadening the customer base, and deepening the pipeline.

• Most units contracted in H1 are expected to be deployed within FY25.

• Ongoing commitment to scalability and meeting rising demand for PhotonAssay units.